We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

NOXXON Pharma AG Announces Preliminary Phase I Trial Results for Spiegelmer® NOX-E36

News   Oct 13, 2009

 
NOXXON Pharma AG Announces Preliminary Phase I Trial Results for Spiegelmer® NOX-E36
 
 
 

RELATED ARTICLES

Existing Drug Could Treat Porphyria

News

An existing antifungal drug, ciclopirox (CPX), has been shown to improve symptoms associated with congenital erythropoietic porphyria – the rarest type of porphyria.

READ MORE

Obesity & Vitamin D Deficiency May Indicate Greater Breast Cancer Risk

News

New study demonstrates that postmenopausal women have an increased risk of vitamin D deficiency at the time of breast cancer diagnosis, associated with a higher rate of obesity.

READ MORE

Experimental Nasal Influenza Vaccine Tested in Kids, Teens

News

NIH-supported Phase 1 trial of potential broadly protective vaccine.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE